Monterey Bio Acquisition Corp. (MTRYU) Prices $100M IPO

Monterey Bio Acquisition Corp. announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “MTRYU” Friday, October 1.

The Company intends to partner with a biotech company, specifically within the oncology or immunology sector, that has demonstrated success and is primed to thrive in the rapidly evolving biotech industry. Monterey Bio is led by CEO Sanjeev Satyal along with CFO William McKeever.

Total SPAC deal count for 2021 year-to-date is now 448. This offering is expected to close on Tuesday, October 5.

Chardan Capital Markets LLC is the sole book running manager for the offering.  Greenberg Traurig, LLP is serving as Issuer’s Counsel with Reed Smith LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.